News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs
A Highly Specialised Technologies programme will evaluate increasingly niche and expensive biologics and gene therapies like Glybera, says NICE as it publishes guidance recommending the funding of Alexion’s Soliris.
Italy has suspended the use of Fluad despite Novartis saying no causal relationship has been established between its seasonal flu vaccine and three deaths.
Regulatory fast-tracking and researchers working weekends are behind GSK's speedy Phase I Ebola vaccine trial, the company says.